Heron Therapeutics is a deeply distressed but potentially asymmetric biotech turnaround, where ZYNRELEF’s reimbursement-driven acute-care ramp must outrun CINVANTI generic erosion, debt pressure, and Nasdaq delisting risk.
Heron Therapeutics, Inc. (HRTX) operates as a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations that improve the standard of care for patients in post-surgical pain management and supportive oncology care.[1, 2] The company’s commercial model centers on two distinct portfolios: the Acute Care franchise and the Oncology Supportive Care franchise.[2, 3] Geographically, the company's operations and revenues are heavily concentrated within the United States market.[2]
The company generates revenues from net product sales across four proprietary FDA-approved formulations, distributed to hospital networks, ambulatory surgery centers (ASCs), oncology clinics, and infusion centers [2, 4]:
| Product Segment | Brand Name | Active Ingredient(s) | Primary Clinical Indication |
|---|---|---|---|
| Acute Care | ZYNRELEF [2] | Bupivacaine and Meloxicam [5] | Post-surgical local analgesia for up to 72 hours [5] |
| Acute Care | APONVIE [2] | Aprepitant [3] | Prevention of postoperative nausea and vomiting (PONV) [3] |
| Oncology Supportive Care | CINVANTI [2] | Aprepitant [6] | Prevention of chemotherapy-induced nausea and vomiting (CINV) [6] |
| Oncology Supportive Care | SUSTOL [2] | Granisetron [7] | Extended-release prevention of acute and delayed CINV [3, 7] |
The primary customers for the Acute Care franchise are surgical centers, operating departments, and hospital procurement systems.[2, 4] For the Oncology Supportive Care franchise, the primary customers are cancer clinics, oncology GPOs, and outpatient infusion centers.[2]
Clinicians and healthcare institutions choose Heron’s products over cheaper generic alternatives due to demonstrated clinical superiority and administrative convenience. ZYNRELEF is the first and only dual-acting local anesthetic to demonstrate in Phase 3 clinical trials a statistically significant reduction in pain and a significantly higher proportion of patients requiring no opioids through the critical 72-hour postoperative window compared to the historical standard-of-care bupivacaine solution.[3, 5] APONVIE provides the same active ingredient as CINVANTI in a rapid 30-second intravenous (IV) push, offering immediate therapeutic levels and improving operational efficiency in busy surgical units compared to multi-dose oral regimens or slower IV alternatives.[3, 6]
SPECULATIVE TRANSITION PROFILE
Heron’s commercial focus is in the midst of a pivot from its mature oncology business to its high-growth acute care assets.[8, 9] ZYNRELEF represents a proprietary polymer-based formulation utilizing the Biochronomer drug delivery platform to deliver a fixed-dose combination of bupivacaine and low-dose meloxicam directly into the surgical wound.[5, 10, 11] This delivery mechanism provides sustained local release of both the anesthetic and anti-inflammatory agent, maintaining analgesia for three postoperative days.[5]
APONVIE and CINVANTI utilize a proprietary polysorbate 80-free injectable emulsion of aprepitant.[6, 12] By eliminating polysorbate 80, a common excipient in rival formulations, Heron's products minimize the risk of hypersensitivity reactions and injection site pain, allowing CINVANTI and APONVIE to be administered as rapid IV pushes.[3, 6]
To expand its Acute Care market penetration, Heron is executing two primary product optimization initiatives:
* The Vial Access Needle (VAN) Program: The VAN is designed to replace the legacy Vented Vial Spike (VVS) in the ZYNRELEF package.[10, 12] The VVS required up to three minutes of preparation and manual coordination.[10] The VAN simplifies the aseptic preparation process, reducing withdrawal times to between 20 and 45 seconds.[10] The corporate transition to the VAN was completed in the third quarter of 2025.[4]
* The Prefilled Syringe (PFS) Lifecycle Program: The PFS is a late-stage lifecycle project aimed at delivering ZYNRELEF in a ready-to-use format.[13, 14] Registration batches have been manufactured and placed on stability testing.[13, 14] Management expects 12-month stability data in the first quarter of 2027 to support FDA filing, targeting commercial launch in mid-to-late 2027.[13, 14]
Heron’s economic moat is primarily built around its proprietary Biochronomer polymer formulation technology, specialized manufacturing processes, and administrative barriers within hospital procurement channels.[2, 3, 11] The manufacturing of stable, sterile oil-in-water emulsions and polymer-based delivery formulations represents a high technical hurdle for prospective generic developers.[11, 15]
Additionally, hospital formulary inclusion creates switching costs.[2, 3] Securing Pharmacy and Therapeutics (P&T) approvals requires significant clinical and administrative effort.[2, 3] Once clinicians integrate specific post-surgical protocols (such as ZYNRELEF or APONVIE) into computerized physician order entry (CPOE) systems, they are historically reluctant to revert to generic local anesthetics.[2, 3]
However, Heron's intellectual property moat has recently faced severe legal challenges.[16, 17] The Delaware District Court's invalidation of key CINVANTI patents significantly weakens the company’s legal defense against immediate generic competition.[16, 17]
The addressable market for Heron's Acute Care portfolio is expanding, primarily driven by legislative tailwinds.[3, 12] The Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act provides separate reimbursement under the Medicare Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) payment frameworks.[3, 8, 12] Historically, long-acting non-opioid anesthetics were financially penalized because their costs were bundled into standard surgical payments.[8] Under the NOPAIN Act, CMS pays separately for non-opioid pain options like ZYNRELEF (under permanent J-code J0668).[3, 12] This regulatory change expands ZYNRELEF’s addressable market to approximately 13 million to 14 million eligible orthopedic and soft tissue surgical procedures in the U.S. annually.[6, 7, 18]
For APONVIE, the active J-code (J8502) streamlines outpatient billing across commercial and Medicare channels.[3, 13] The therapy is positioned to address the subset of 35 million annual surgical patients in the U.S. who exhibit moderate-to-high risk profiles for PONV.[3, 4]
In post-surgical pain management, Heron’s primary competitor is Pacira BioSciences, Inc., which commercializes Exparel (liposomal bupivacaine).[19] Exparel is the leading branded long-acting local anesthetic, generating over \$400 million in annual product sales.[19] Heron is positioned against Pacira through direct clinical comparisons and competitive pricing.[19, 20] ZYNRELEF has demonstrated clinical superiority over standard bupivacaine in Phase 3 head-to-head registration trials.[19, 20]
Furthermore, Heron has structured ZYNRELEF's Wholesale Acquisition Cost (WAC) at a discount to Exparel [19, 20]:
| Product (Anesthetic Solution) | Core Dosage | WAC Price Comparison (U.S. USD) | Relative Price Advantage |
|---|---|---|---|
| Exparel (Liposomal Bupivacaine) [19] | 266 mg [19] | \$344.20 [19] | Baseline |
| ZYNRELEF (Extended-Release) [19] | 400 mg / 12 mg [19] | \$267.50 [19] | 22.3% WAC Discount [19, 20] |
ZYNRELEF is also sold at a 41% discount to Exparel's pricing inside eligible 340B hospital accounts.[20] However, Exparel maintains a substantial head start in clinical adoption, larger commercial budgets, and a broader clinical label that includes regional nerve blocks.[20]
In the Oncology Care segment, CINVANTI maintains a 25% market share in the NK1 receptor antagonist class.[3] However, the segment is facing competitive pressure and generic legal challenges.[16, 17]
INTENSE REIMBURSEMENT-DRIVEN PIPELINE
Heron announced its first-quarter 2026 financial results on May 11, 2026, delivering performance that fell below Wall Street consensus expectations.[21, 22] The company reported total net product sales of \$34.711 million, missing the Zacks Consensus Estimate of \$36.13 million and wider consensus expectations of \$36.7 million to \$39.28 million.[21, 23, 24] This represents a year-over-year revenue decline of 10.8% compared to the \$38.903 million recorded in Q1 2025.[23, 25]
The company reported a GAAP net loss of \$8.111 million, compared to a GAAP net income of \$2.560 million in Q1 2025.[25] This resulted in a GAAP basic loss per share of (\$0.04), missing Wall Street estimates of (\$0.015) to (\$0.02) per share.[21, 23, 24, 26] Adjusted EBITDA was negative \$727,000.[21]
| Product Segment & Products | Q1 2026 Net Sales (USD) | Q1 2025 Net Sales (USD) | Year-over-Year Change | Performance Relative to Estimates |
|---|---|---|---|---|
| Acute Care Segment [3] | \$13,629,000 [3] | \$10,302,000 [3] | +32.3% [3] | Missed Combined Target [21] |
| - ZYNRELEF [3] | \$10,235,000 [3] | \$8,042,000 [3] | +27.3% [3] | Missed average estimate of \$11.65M [23] |
| - APONVIE [3] | \$3,394,000 [3] | \$2,260,000 [3] | +50.2% [3] | Missed average estimate of \$3.73M [23] |
| Oncology Supportive Care [3] | \$21,082,000 [3] | \$28,601,000 [3] | -26.3% [3] | Missed Combined Target [21] |
| - CINVANTI [3] | \$20,535,000 [3] | \$25,742,000 [3] | -20.2% [3] | Missed average estimate of \$21.00M [23] |
| - SUSTOL [3] | \$547,000 [3] | \$2,859,000 [22] | -80.9% [3] | Missed average estimate of \$1.00M [23] |
| Total Net Revenue [3] | \$34,711,000 [3] | \$38,903,000 [25] | -10.8% [23] | Missed consensus of \$36.7M–\$39.28M [21, 24] |
Heron’s management reaffirmed its full-year 2026 guidance despite the challenging first-quarter results.[3, 22] The guidance forecasts net revenues between \$173 million and \$183 million, and Adjusted EBITDA between \$10 million and \$20 million.[3, 22]
CEO Craig Collard highlighted that severe winter weather early in 2026 delayed elective surgeries, which are sensitive to extreme conditions.[21] However, he emphasized that March net product sales exceeded \$15 million, indicating a post-winter recovery.[21]
CFO Ira Duarte noted that gross margin fell to 69.4% in Q1 2026, down from 78.3% in Q1 2025.[8] This compression was attributed to inventory adjustments and the transition away from higher-cost CINVANTI stock, with gross margins expected to normalize over the next two quarters.[8, 22] Management reiterated that existing cash, cash equivalents, and short-term investments of \$44.8 million are projected to support operations into the second half of 2027.[27, 28]
Following the earnings announcement, the stock declined 16.94% during open market trading, falling from \$1.24 to \$0.98.[21] The stock was further pressured on June 2, 2026, following the Delaware District Court's CINVANTI patent ruling.[16, 29] This resulted in a 45.6% single-day decline, pushing the stock to a multi-year low.[29]
Analyst ratings and price targets were revised downward following these events.[30] Needham downgraded HRTX from Buy to Hold.[30] H.C. Wainwright initially adjusted its price target from \$6.00 to \$4.00 following the Q1 earnings release, and later cut it to \$2.00 after the patent decision.[24, 30]
To evaluate Heron’s valuation, investors must analyze its historical top-line growth against its debt-laden capital structure.[28, 31] Over the last five fiscal years, Heron’s annual revenue grew from \$88.63 million in 2020 to \$154.90 million in 2025.[31, 32] This represents a 5-year sales compound annual growth rate (CAGR) of 11.81%:
$\text{CAGR}_{2020-2025} = \left(\frac{\$154.90\text{ million}}{\$88.63\text{ million}}\right)^{\frac{1}{5}} - 1 \approx 11.81\%$ [31, 32]
The stock trades at a Price-to-Sales (P/S) multiple of approximately 0.53x based on trailing twelve-month (TTM) revenues of \$150.70 million and a share price of \$0.43.[33, 34, 35] This is lower than the U.S. biotech industry average of 9.7x.[33]
This multiple reflects the financial risk associated with \$141.63 million in outstanding debt against \$9.14 million in total shareholder equity, representing a debt-to-equity ratio of 1,550.1%.[28] The company's valuation is sensitive to its ability to transition its revenue mix toward the higher-margin Acute Care franchise before its cash reserves are depleted.[8, 28, 33]
REVENUE PIVOT VS DEBT
The primary company-specific risk is the commercial ramp of the Acute Care portfolio.[33] Heron is executing a major commercial expansion in the third quarter of 2026, adding additional sales representatives to drive ZYNRELEF and APONVIE adoption.[4, 22] If these efforts fail to translate into rapid unit volumes, the company's operating cash burn will accelerate, shortening its cash runway.[27, 33]
Additionally, product-line changes (e.g., transitioning from the VVS to the VAN, and developing the PFS format) carry manufacturing and clinical adoption risks.[10, 12]
Heron faces competition from Pacira’s Exparel.[19] Exparel holds a dominant market share in post-surgical pain management and is supported by a larger sales team and well-established clinical workflows.[19, 20] If Pacira lowers its pricing or expands Exparel's clinical indications, it could restrict ZYNRELEF's market penetration.[19, 20]
Heron’s Acute Care sales are dependent on hospital P&T committee approvals and GPO contract alignments.[2, 3] A consolidated decision by a major hospital network or GPO to restrict ZYNRELEF or APONVIE from its formularies represents a significant demand risk.[2, 3] Furthermore, post-surgical pain product volumes are sensitive to the scheduling of elective surgeries, which can be impacted by external variables like hospital staffing shortages or extreme weather.[21]
The primary regulatory risk is the company's current listing deficiency with the Nasdaq Capital Market.[36, 37] On June 25, 2026, the company received notice that its stock had failed to maintain the \$1.00 minimum bid price requirement for 30 consecutive trading days.[36, 37] The company has until December 22, 2026, to cure this deficiency by maintaining a closing bid of at least \$1.00 for ten consecutive trading days.[36, 37] Failure to regain compliance could lead to delisting, reducing stock liquidity and limiting future equity financing options.[37]
On the legal front, the Delaware District Court's June 1, 2026 ruling holding asserted claims of patents 12,115,255 and 12,290,520 invalid creates risk for CINVANTI’s market exclusivity.[17, 29] While settlements with Mylan (license to market generic starting June 1, 2032) and Baxter remain in place, Azurity (which acquired Slayback) could potentially launch a generic aprepitant emulsion sooner, depending on the outcome of Heron’s appeal to the Federal Circuit.[3, 16, 17, 38]
Heron's capital structure carries significant financial risk.[16, 28] The company's working capital facility with Hercules Capital carried a carrying value of \$108.3 million as of March 31, 2026.[8, 25] This facility carries an expensive floating interest rate of Prime plus 1.95% (with a 7.5% floor) and a 1.0% annual PIK interest rate, alongside an end-of-term fee of up to 6.5%.[25]
The agreement also contains restrictive financial covenants, including minimum cash, revenue, and EBITDA targets.[25] Any operational underperformance could trigger a covenant breach, forcing highly dilutive equity raises or technical default.[25, 29]
Heron is sensitive to inflationary pressures and rising interest rates.[21, 25] Inflation can increase the costs of active pharmaceutical ingredients (APIs) and direct manufacturing inputs, squeezing gross margins.[8] Rising interest rates directly increase the company's debt service costs under the floating-rate Hercules facility.[25]
HIGH OPERATIONAL RISK
This 5-year scenario analysis projects Heron's operating performance and implied equity value from fiscal year-end 2025 through fiscal year-end 2030, using the June 26, 2026 closing share price of \$0.43 USD as the baseline.[34, 35]
The Base Case assumes ZYNRELEF adoption is supported by the NOPAIN Act, helping offset the gradual generic erosion of CINVANTI.[12, 17] Total revenue is projected to reach \$269.00 million by 2030, representing a 5-year CAGR of 11.66% relative to the \$154.90 million recorded in FY2025.[31, 34] Operational leverage allows the company to reach a GAAP net margin of 17.47%, generating a net profit of \$47.00 million.[34]
To fund operations through early 2028, Heron is assumed to execute additional dilutive capital raises [28, 33], expanding the outstanding share count by approximately 10% to 208.21 million.[34, 40] Applying a forward P/E multiple of 12.0x to reflect resolved debt maturities and a stabilized capital structure implies a future market capitalization of \$564.00 million.
$\text{Market Capitalization} = \$47.0\text{ million} \times 12.0 = \$564.0\text{ million}$
$\text{Implied Future Share Price} = \frac{\$564,000,000}{208,208,000\text{ shares}} \approx \$2.71\text{ USD}$
This implies a 5-year total return of 530.2% and an annualized return of 44.5%.
The High Case assumes Heron wins its Federal Circuit appeal, preserving CINVANTI’s market exclusivity.[17, 29] ZYNRELEF’s PFS format launches on schedule in mid-2027, accelerating clinical adoption.[13, 14] Total revenue is assumed to reach \$350.00 million by 2030, driven by the expansion of the Acute Care portfolio.[9]
The company achieves a GAAP net margin of 22.0%, resulting in a net profit of \$77.00 million.[34] With strong operating cash flows, dilution is restricted, keeping the outstanding share count at 200.00 million.[40] Reflecting this stronger growth profile, a forward P/E multiple of 15.0x is applied, implying a market capitalization of \$1.155 billion.
$\text{Market Capitalization} = \$77.0\text{ million} \times 15.0 = \$1,155.0\text{ million}$
$\text{Implied Future Share Price} = \frac{\$1,155,000,000}{200,000,000\text{ shares}} \approx \$5.78\text{ USD}$
This implies a 5-year total return of 1,244.2% and an annualized return of 68.1%.
The Low Case reflects a distressed scenario. Heron's patent appeal is rejected, enabling Azurity to launch a generic aprepitant emulsion in 2027.[16, 17] Concurrently, ZYNRELEF’s commercial adoption is limited by competitive pressures.[19] Total revenue stagnates and falls to \$130.00 million by 2030.[33]
The company records a net loss of (\$10.00 million) (a net margin of -7.69%).[34] To satisfy debt obligations, the company executes dilutive stock offerings [28, 33], driving the outstanding share count to 350.00 million. Applying a distressed terminal P/S multiple of 0.20x implies a market capitalization of \$26.00 million.
$\text{Market Capitalization} = \$130.0\text{ million} \times 0.20 = \$26.0\text{ million}$
$\text{Implied Future Share Price} = \frac{\$26,000,000}{350,000,000\text{ shares}} \approx \$0.07\text{ USD}$
This implies a 5-year total return of -83.7% and an annualized return of -30.3%.
The probability-weighted share price target, calculated across these three scenarios, is structured below:
$\text{Weighted Price Target} = (\$2.71 \times 0.50) + (\$5.78 \times 0.25) + (\$0.07 \times 0.25) = \$1.355 + \$1.445 + \$0.0175 \approx \$2.82\text{ USD}$
| Scenario | Revenue in Year 5 (2030) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price (USD) | Implied Future Share Price (USD) | 5-Year Total Return | Annualized Return | Subjective Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | \$350.0M [9] | 22.0% Margin / \$77.0M Net Income [34] | 15.0x P/E [34] | \$0.43 [34] | \$5.78 | 1,244.2% | 68.1% | 25% |
| Base Case | \$269.0M [34] | 17.5% Margin / \$47.0M Net Income [34] | 12.0x P/E [34] | \$0.43 [34] | \$2.71 | 530.2% | 44.5% | 50% |
| Low Case | \$130.0M [33] | -7.7% Margin / (\$10.0M) Net Loss [34] | 0.20x P/S [16, 33] | \$0.43 [34] | \$0.07 | -83.7% | -30.3% | 25% |
| Weighted | \$254.5M | \$40.5M Net Income | N/A | \$0.43 | \$2.82 | 555.8% | 45.6% | 100% |
ASYMMETRIC SPECULATIVE RETURN
This qualitative scorecard evaluates Heron’s core operational, corporate, and structural attributes. Each category is rated on a 1–10 scale, accompanied by an analytical narrative.
CEO Craig Collard holds 662,052 shares directly, alongside restricted stock units.[41] However, direct insider ownership among the executive team and board is relatively low at approximately 6.10%.[42]
The CEO's yearly compensation of \$3.52 million is high relative to peer biotechnology companies of similar market capitalization.[43] Additionally, this compensation has increased despite the company remaining unprofitable.[43] While there have been minor insider purchases, the executive compensation structure is heavily weighted toward time-based equity awards rather than operational performance goals.[16, 41, 44]
Heron’s revenue stream is divided between its mature Oncology Care segment and its early-stage Acute Care segment.[2, 3] CINVANTI sales are under pressure due to legal and competitive factors.[16, 17]
In contrast, ZYNRELEF and APONVIE provide higher-quality revenues supported by permanent J-codes and unique clinical profiles.[3, 12] However, these products do not yet generate sufficient sales volume to cover corporate overhead.[33]
The company markets clinically validated products but holds a challenging market position.[2] In the post-surgical pain segment, ZYNRELEF is positioned against Pacira’s Exparel, which benefits from an established clinical presence and larger commercial budget.[19, 20]
In the Oncology Care segment, CINVANTI is a competitive product but faces generic pressure.[3, 16, 17]
The company’s growth outlook is supported by favorable structural drivers.[9] The implementation of the NOPAIN Act separate reimbursement provides a tailwind for ZYNRELEF in outpatient and ASC settings.[3, 12]
Additionally, the development of the prefilled syringe format for 2027 and APONVIE’s formulary expansion support a double-digit top-line growth trajectory.[4, 13, 22]
Heron exhibits weak financial health.[16, 28] The company carries a high debt load of \$141.63 million against shareholder equity of \$9.14 million, resulting in an unsustainable debt-to-equity ratio of 1,550.1%.[28]
The company continues to record operational losses, and high interest expenses under its floating-rate credit facility represent a significant drag on cash flow.[8, 25]
Heron’s business is supported by its portfolio of FDA-approved products.[1, 2] However, its long-term viability depends on transitioning its revenue mix toward the higher-margin Acute Care segment.[8]
If CINVANTI revenues decline faster than Acute Care scales, the company faces structural challenges.[28, 33]
While the August 2025 refinancing eliminated near-term debt maturities and extended debt terms to 2030, it came at a high cost.[45] The Hercules Capital facility features expensive floating rates and cash-preservation penalties, such as PIK interest and end-of-term fees.[25]
Furthermore, historical capital allocation has resulted in heavy shareholder dilution and high sales and marketing overhead, which has delayed the timeline to self-sustained profitability.[33, 46]
Sell-side analyst sentiment is divided.[30] Following the CINVANTI patent invalidation, several firms cut their ratings to Hold or reduced their price targets.[30]
However, the consensus price target remains between \$2.00 and \$4.17, indicating that analysts still recognize potential value in the Acute Care portfolio once legal and delisting overhangs are resolved.[24, 34, 47]
Heron is consistently unprofitable on a GAAP basis, with a net loss of \$8.11 million in Q1 2026 and negative operating margins.[25, 39]
While the company has previously reported positive non-GAAP Adjusted EBITDA, interest expenses and high commercialization costs continue to prevent the company from generating positive GAAP earnings or consistent free cash flow.[8, 9, 31]
Heron has a history of shareholder value dilution.[48] The stock has declined significantly from its historical highs, and its recent decline below the \$1.00 threshold reflects a lack of execution consistency.[37, 49]
Repeated dilutive financings and delayed product launches have impacted institutional trust, resulting in a poor long-term track record of value creation.[33, 48]
A weighted review of these categories results in an overall blended score of 3.5 / 10. This score reflects the divergence between Heron’s clinically validated products and its weak balance sheet, debt obligations, and litigation challenges.[16, 17, 28, 33]
HIGH SPECULATIVE RISK
Heron Therapeutics, Inc. (HRTX) presents a speculative, binary investment profile.[16, 33] The company's investment thesis represents a race between the commercial adoption of its Acute Care portfolio and the generic erosion of its Oncology franchise [8]:
In summary, Heron is valued as a highly speculative asset.[16, 33] If the company can successfully appeal its patent invalidation or scale ZYNRELEF rapidly, the stock is undervalued at current levels.[16, 17, 34] However, if the generic CINVANTI launch proceeds and the Acute Care expansion underperforms, equity holders face severe financial risk.[16, 28, 33]
SPECULATIVE BINARY PLAY
Heron's common stock is currently trading in a depressed range of \$0.41 to \$0.44 USD [34, 35], representing a 60.4% discount to its declining 200-day moving average of \$1.0866.[50] This sharp technical breakdown was triggered by the June 2, 2026 CINVANTI patent invalidation ruling [29] and was compounded by the June 25, 2026 Nasdaq delisting notice.[36]
The short-term technical outlook remains weak, characterized by bearish momentum and significant overhead resistance.[35, 51] In the absence of a near-term catalyst—such as a successful patent appeal, a favorable settlement, or a reverse stock split—the stock is highly vulnerable to continued volatility as it struggles to regain the \$1.00 minimum bid threshold before the December 22, 2026 deadline.[29, 37]
BEARISH MOMENTUM OVERHANG
View Heron Therapeutics, Inc. (HRTX) stock page
Loading the interactive version of this report…